Recent News

• 09.04.2025 - IO Biotech Announces Participation in Upcoming Investor Conferences
• 08.14.2025 - IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
• 08.11.2025 - IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
• 08.10.2025 - IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Recent Filings

• 08.19.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 8-K Current report
• 07.31.2025 - EFFECT Notice of Effectiveness
• 07.29.2025 - UPLOAD SEC-generated letter
• 07.29.2025 - CORRESP Correspondence
• 07.24.2025 - S-3 Registration statement under Securities Act of 1933